Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men.

Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men. Adv Pharmacol Sci. 2018;2018:4673061 Authors: Hadzi-Petrushev N, Dimovska K, Jankulovski N, Mitrov D, Mladenov M Abstract Oxidative stress and inflammation contribute to the pathogenesis and progression of nonalcoholic fatty liver disease (NAFLD), and the control of lipid status by statins may help to stop the progression of NAFLD. We hypothesized that the addition of antioxidant vitamins C and E to atorvastatin therapy is associated with improved serum enzyme antioxidant status. NAFLD-related serum parameters and the activity of antioxidant enzymes, before and after 3 months of treatment, were determined in patients receiving atorvastatin alone or atorvastatin plus antioxidants. Compared to healthy controls, the patients, before receiving therapy, had increased catalase and glutathione reductase, with no significant difference in glutathione peroxidase activity. After the treatment, the levels of all three antioxidant markers were reduced to the same degree in both groups of patients, indicating therapy-induced lower level of reactive oxygen species production and/or improved nonenzymatic antioxidant mechanisms. Both therapies led to the normalization of the serum lipid profile and aminotransferase levels in the patients, but the reduction in CRP, although significant, did not reduce levels to those of the controls. The obtained results fa...
Source: Advances in Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Adv Pharmacol Sci Source Type: research

Related Links:

Abstract Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. Its prevalence is increasing because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality in NAFLD/NASH patients. Current guidelines suggest the use of p...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
Might most patients with suspected non-alcoholic fatty liver disease benefit from statin therapy?Liver International
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Publication date: Available online 27 June 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Sneha Kothari, Hiteshi Dhami-Shah, Samir R. ShahNonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease worldwide. Despite its high prevalence and rising incidence, there are currently no specific targeted pharmacotherapies approved by the Food and Drug Administration (FDA) for nonalcoholic steatohepatitis (NASH). Current therapies for patients with NAFLD include lifestyle modification. Vitamin E and pioglitazone are recommended for those confirmed to have NASH. However, there are co...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Publication date: Available online 27 June 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Sneha Kothari, Hiteshi Dhami-Shah, Samir R. ShahAbstractNonalcoholic Fatty Liver Disease (NAFLD) has become the most prevalent liver disease worldwide. Despite its high prevalence and rising incidence there are currently no specific targeted pharmacotherapies approved by FDA for NASH. Current therapies for patients with NAFLD include life style modification. Vitamin E and pioglitazone are recommended in those confirmed to have nonalcoholic steatohepatitis (NASH). However, there are concerns about the long term s...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
AbstractPurposeElevated copeptin, a vasopressin marker, is linked to metabolic disease, and obese rats with low-vasopressin concentration had a decreased risk of liver steatosis. We here investigated the association between copeptin and nonalcoholic fatty liver disease (NAFLD) and possible differences in copeptin concentration between ethnicities.MethodsIn this cross-sectional study of 361 South Africans (n = 172 African black, 189 = Caucasian) with a mean age of 45 years and 45% men, plasma copeptin was measured and associated with NAFLD according to a validated fatty liver index accounting for...
Source: Endocrine - Category: Endocrinology Source Type: research
CONCLUSIONS: In a "real-life" general population, the association between vitamin D deficiency and unexplained elevated ALT is specific for non-obese men. The clinical significance of vitamin D for human NAFLD should be further elucidated with attention for a modifying effect of gender and adiposity. PMID: 31103458 [PubMed - as supplied by publisher]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, insulin resistance (IR) and the metabolic syndrome (MetS) and is a leading cause of cirrhosis [1,2]. Its global prevalence is 25% [3] and is increasing worldwide [4] accompanied by severe complications particularly in high-risk older obese patients [5]. Thiazolidinediones, statins and vitamin E have been proposed for the management of NAFLD [6,7] together with lifestyle modifications [8], but there is currently no specifically approved medication.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research
Background: Youth-onset type 2 diabetes (T2D) is increasing in many countries, creating large personal and societal burdens. While many primary health-care professionals (HCPs) are aware of the classic symptoms of T2D, there are several other manifestations that could indicate its presence.Summary: This narrative review summarizes information on these symptoms and indicators, focusing on those less well known. The classic symptoms and comorbidities include frequent urination, excessive thirst, metabolic syndrome, and obesity. In addition to these, the presence of dermatological (e.g., acanthosis nigricans, granuloma annula...
Source: Annals of Nutrition and Metabolism - Category: Nutrition Source Type: research
Conclusions: While there is a certain overlap between the results of the current study and published transcriptomic profiles of non-transplanted livers with steatosis, we have identified discrete characteristics of the non-alcoholic fatty liver disease in liver grafts potentially utilizable for the establishment of predictive signature. Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in industrialized countries, its prevalence being estimated at 19–31.3% (1). It encompasses a range of conditions that are thought to arise from fatty liver (simple steatosis) throu...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Conclusions: The lipidome is altered in ART-treated HIV infection, and may contribute to inflammation and CVD progression. Detailed lipidomic analyses may better assess CVD risk in both HIV+ and HIV– individuals than does traditional lipid profiling. Introduction Both HIV infection and the use of antiretroviral therapy (ART) contribute to an increased risk for cardiovascular disease (CVD) (1, 2). Dyslipidemia is observed in HIV-infected (HIV+) individuals, and is associated with reduced levels of high-density lipoprotein (HDL) cholesterol, and elevated total (TC) cholesterol, low-density lipoprotein (LDL) chole...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Antidoxidants | Atorvastatin Calcium | Cholesterol | Drugs & Pharmacology | Fatty Liver Disease (FLD) | Lipitor | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Statin Therapy | Urology & Nephrology | Vitamin C | Vitamins | Zivast